ASX Announcements
Date of AGM and Closing Date for Director Nominations
Notice of Meeting - Other, Company Administration - Other
- Sep 25, 2024
- 2 pages
Application for quotation of securities - ACW
Appendix 2A (Application for Quotation of Securities)
- Sep 24, 2024
- 7 pages
September
Alzheimer’s drug developer Actinogen rattles the tin
Actinogen would use the proceeds to expand the Phase 2b trials of its XanaMIA treatment for Alzheimer’s to a full enrolment of 220 patients.
- Sarah Thompson, Kanika Sood and Emma Rapaport
October 2020
Bell Potter raising for Alzheimer's drug hopeful Actinogen
ASX-listed Actinogen Medical is in front of potential investors seeking a $10 million equity injection to fund a trial for its Alzheimer's drug.
- Sarah Thompson, Anthony Macdonald and Tim Boyd
December 2017
Actinogen Medical raises $5.2m for Alzheimer's treatment
Alzheimer's disease is the second biggest killer of Australians, but investors have just bet $5.3 million that an ASX-listed company has the cure.
- Michael Bailey
January 2016
- Opinion
In innovation and biotech let's party like it's 1998
Conditions may be bad but in 1997 they were also bad and 1998 was expected to be far worse, but then the sharemarket boomed.
- Updated
- Martin Rogers